Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
2.100
+0.260 (14.13%)
Nov 21, 2024, 2:56 PM EST - Market open
Quince Therapeutics Employees
Quince Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 11 or 52.38% compared to the previous year.
Employees
32
Change (1Y)
11
Growth (1Y)
52.38%
Revenue / Employee
n/a
Profits / Employee
-$1,664,500
Market Cap
92.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
I-Mab | 220 |
OptimizeRx | 136 |
Armata Pharmaceuticals | 66 |
Aerovate Therapeutics | 51 |
ESSA Pharma | 50 |
Werewolf Therapeutics | 47 |
Clearside Biomedical | 30 |
QNCX News
- 7 days ago - Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
- 8 days ago - Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research - Business Wire
- 9 days ago - Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting - Business Wire
- 5 weeks ago - Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - Business Wire
- 3 months ago - Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex - Seeking Alpha
- 3 months ago - Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - Business Wire
- 3 months ago - Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - Business Wire